EGFR and neoplasm: Dynamic changes in EGFR activating and resistance mutation levels detected in urine are associated with tumor response within days of therapy for NSCLC patients receiving anti-EGFR tyrosine kinase inhibitors; Daily sampling of circulating tumor DNA (ctDNA) has potential for early assessment of treatment response